We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Knocking on the door

30 August 2010 By Pierre Briancon

The U.S. biotech wants a bigger offer before talking. The French pharma group, meanwhile, has gone public with its lowball $69ashare offer, hoping to pressure its target into talks that might yield a higher price. But Sanofi’s threat of a hostile bid looks hollow for now.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)